Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

View all →   RSSRecent Releases
Oct 9, 2016 Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma Meets Primary Overall Response Endpoint and Demonstrates Clinically Meaningful Duration of Response
Sep 23, 2016 Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
More →Upcoming Events
Details on upcoming events are not yet available.
Featured Financial Reports
Filing Date Title Type Size
Aug 8, 2016 Form 10-Q View HTML View PDF 328.0 KB Add to Briefcase
Feb 25, 2016 Form 10-K/A View HTML View PDF 1.1 MB Add to Briefcase
Add to Briefcase = add file to Briefcase